The limited efficacy of BRAF inhibitors given as single agents in patients with BRAF-mutant CRC led to investigations of the combination of BRAF and EGFR inhibitors, demonstrating improved activity [106,107,108]. This evidence concerns the gene BRAF and colorectal carcinoma.